Pumitamig

BNT327

Dual PD-L1 × VEGF-A Antibody Pumitamig Delivers Strong Phase 2 Results in ES-SCLC

At WCLC 2025, pumitamig (BioNTech/BMS) demonstrated 76% ORR and 100% disease control in ES-SCLC, outperforming current PD-L1 monotherapies. The bispecific antibody combines checkpoint blockade and anti-angiogenesis for enhanced efficacy.

WCLC 2025: China-Origin BNT327 (PD-L1/VEGF-A) Delivers Breakthrough ES-SCLC Results

At WCLC 2025 (Sep 6–9), China-origin BNT327 (pumitamig), a PD-L1/VEGF-A bispecific, shows promising efficacy in first-line ES-SCLC. Abstract data were published Aug 20, 2025, marking the first global dataset for this China-origin therapy.